3 Humongous Health Care Stocks This Week
Motley Fool
Ariad's Cancer Drug Iclusig Extends The Gleevec Magic
Seeking Alpha
ARIAD presents new preclinical data on ponatinib
The Fly on the Wall
Can Bristol-Myers Squibb Compete In Immuno-Oncology?
Seeking Alpha
Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine
TheStreet.com
The Survey Says: Ariad's Leukemia Drug Is Toxic
TheStreet.com
Ariad Pharma Falls On Weak Leukemia Drug Prescriptions
TheStreet.com

